[Experimental basis and clinical evaluation of indomethacin efficacy in patients with ischemic stroke].
Experimental work provides evidence for a benefit from indometacinum use (3 mg/kg daily for 4 days) in model of focal brain ischemia in rabbits was. The efficacy of this drug (25 mg 3 times a day for 14-18 days) in patients with ischemic stroke has been studied. The focal brain ischemia in rabbits was induced by 3 hours' bilateral occlusion of common carotid arteries. After that several parameters of hydroionic homeostasis, lactatdehydrogenase and superoxide dismutase were measured in serum and CSF. Neurological status, hemostasis parameters and blood lipid spectrum were examined in patients with ischemic stroke. The results clearly show the antihypoxic effect of indometacinum by bringing ion balance as well as the activities of lactate dehydrogenase's and superoxide dismutase to normal values. Decrease of neurological deficit, improvement of lipid spectrum and haemocoagulating system were observed in the treated patients with ischemic stroke.